Drug-induced lupus

被引:12
|
作者
Aguirre Zamorano, Ma Angeles [1 ]
Lopez Pedrera, Rosario [2 ]
Cuadrado Lozano, Ma Jose [3 ]
机构
[1] Hosp Univ Reina Sofia, Serv Reumatol, Cordoba, Spain
[2] Hosp Univ Reina Sofia, Unidad Invest, Cordoba, Spain
[3] St Thomas Hosp, Raine Inst, Lupus Res Unit, London, England
来源
MEDICINA CLINICA | 2010年 / 135卷 / 03期
关键词
Autoimmunity; Anti-TNFalfa; Statins; Minocycline; ALPHA THERAPY; ERYTHEMATOSUS; INFLIXIMAB; GLOMERULONEPHRITIS; MANIFESTATIONS; MINOCYCLINE;
D O I
10.1016/j.medcli.2009.04.035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Drug-induced lupus (DIL) is syndrome characterised by the occurrence of lupus-like symptoms and serological findings, following exposure to certain drugs. A substantial number of drugs can induce the positivity of antinuclear antibodies (ANA) but the diagnosis of DIL cannot be done in the absence of clinical features. Most patients with DIL have constitutional symptoms, arthralgia or occasionally arthritis, myalgias, fever and weight loss. These features may take weeks or months to develop and use to be mild with renal and central nervous system happening very rarely. ANA are always positive. They are mainly anti-histone proteins. Antibodies to ds-DNA are a rare finding and would tend to favour a diagnosis of idiopathic SLE. They have been associated with the use of tumour necrosis factor inhibitors (ant-TNF) and minocycline. Some drugs can induce particular symptoms o serological abnormalities and the diagnosis may be more difficult. It is the case of minocycline-induced lupus, which uses to affect young women with anti-ds-DNA and p-ANCA antibodies positive and negative anti-histone antibodies. Treatment with anti-TNF alpha is frequently associated with the development of ANA and anti-DNA. The incidence of ANA positive varies between 23-57% and anti-DNA between 9-33%. However, only a small number of patients will develop DIL or vasculitis.
引用
收藏
页码:124 / 129
页数:6
相关论文
共 50 条
  • [1] Drug-Induced Lupus
    Chengappa, Kavadichanda G.
    INDIAN JOURNAL OF RHEUMATOLOGY, 2019, 14 : S10 - S18
  • [2] DRUG-INDUCED LUPUS
    YUNG, RL
    RICHARDSON, BC
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1994, 20 (01) : 61 - 86
  • [3] DRUG-INDUCED LUPUS
    CHRISTOPHIDIS, N
    LANCET, 1984, 2 (8407): : 868 - 868
  • [4] DRUG-INDUCED LUPUS
    DOVE, FB
    HOSPITAL PRACTICE, 1993, 28 (08): : 14 - 14
  • [5] DRUG-INDUCED LUPUS
    STEVENS, MB
    HOSPITAL PRACTICE, 1992, 27 (3A): : 27 - 36
  • [6] Drug-induced lupus
    Rubin, RL
    TOXICOLOGY, 2005, 209 (02) : 135 - 147
  • [7] Drug-induced lupus
    Borchers, Andrea T.
    Keen, Carl L.
    Gershwin, M. Eric
    AUTOIMMUNITY, PT D: AUTOIMMUNE DISEASE, ANNUS MIRABILIS, 2007, 1108 : 166 - 182
  • [8] DRUG-INDUCED LUPUS
    JACOBS, JC
    JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1972, 222 (12): : 1557 - &
  • [9] Drug-induced lupus
    Rubin, Robert L.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (03) : 361 - 378
  • [10] Drug-induced lupus
    Miyasaka, N
    INTERNAL MEDICINE, 1996, 35 (07) : 527 - 528